NDA 022075 · Kyowa Kirin
Nourianz
Istradefylline · Oral
NovelLast checked: Nov 20, 2026Latest source record: Aug 27, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Aug 27, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
28
12 Phase 3, 1 recruiting
FAERS reports
5,984
2,641 serious, 937 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 20, 2025.
NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes. NOURIANZ is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes ( 1 ).
Mechanism: The precise mechanism by which istradefylline exerts its therapeutic effect in Parkinson’s disease is unknown. In in vitro studies and in in vivo animal studies, istradefylline was demonstrated to be an adenosine A 2A receptor antagonist.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- NOURIANZ · ISTRADEFYLLINE 40MG · TABLET, ORAL · Prescription
- NOURIANZ · ISTRADEFYLLINE 20MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Istradefylline" as an intervention, any sponsor and status, largest first.
- An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018Pivotal-lookingCompleted
Kyowa Kirin, Inc.Industry
NCT00199368 · 1,100 participants · Start Oct 2004 · Primary completion Mar 2007
Drug: Istradefylline ( KW-6002) · For: Parkinson's Disease
Sites: Princeton, New Jersey
- A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's DiseasePivotal-lookingCompleted
Kyowa Kirin Co., Ltd.Industry
NCT01968031 · 613 participants · Start Oct 2013 · Primary completion Oct 2016
Drug: Istradefylline 40 mg; Istradefylline 20 mg and 1 more · For: Idiopathic Parkinson's Disease
Sites: Phoenix, Arizona; Sun City, Arizona; Tucson, Arizona · 89 sites in all
- A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on LevodopaPivotal-lookingCompleted
Kyowa Kirin, Inc.Industry
NCT00199420 · 580 participants · Start Jul 2004 · Primary completion Nov 2005
Drug: Istradefylline (KW-6002) · For: Parkinson's Disease
Sites: Princeton, New Jersey · 2 sites in all
- An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001Pivotal-lookingTerminated
Kyowa Kirin, Inc.Industry
NCT00199381 · 504 participants · Start Oct 2005 · Primary completion Oct 2008
Drug: Istradefylline · For: Parkinson's Disease
Sites: Princeton, New Jersey
- A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's DiseasePivotal-lookingCompleted
Kyowa Kirin Co., Ltd.Industry
NCT00199394 · 405 participants · Start Nov 2004 · Primary completion Oct 2005
Drug: Istradefylline (KW-6002) · For: Parkinson's Disease
Sites: Slough, United Kingdom
- Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking LevodopaPivotal-lookingCompleted
Kyowa Kirin Co., Ltd.Industry
NCT00955526 · 373 participants · Start Jul 2009 · Primary completion Feb 2011
Drug: Istradefylline; Istradefylline and 1 more · For: Parkinson's Disease
Sites: Tokyo, Japan
- A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaPivotal-lookingCompleted
Kyowa Kirin Co., Ltd.Industry
NCT00455507 · 363 participants · Start Mar 2007 · Primary completion Aug 2008
Drug: Istradefylline; Istradefylline and 1 more · For: Parkinson's Disease
Sites: Tokyo, Japan
- 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/CarbodopaPivotal-lookingCompleted
Kyowa Kirin, Inc.Industry
NCT00456794 · 325 participants · Start Mar 2002 · Primary completion Oct 2003
Drug: Istradefylline (KW-6002) · For: Parkinson's Disease
Sites: Princeton, New Jersey
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death726
- drug ineffective634
- hallucination617
- dyskinesia484
- condition aggravated464
- dizziness423
- product dose omission issue363
- constipation357
- fall352
- tremor272
- therapy non-responder252
- insomnia229
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 25 |
| 2019 | 133 |
| 2020 | 1,509 |
| 2021 | 1,206 |
| 2022 | 1,004 |
| 2023 | 610 |
| 2024 | 678 |
| 2025 | 599 |
| 2026 | 207 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nourianz (Istradefylline)
2024 spending
$50.7M
Beneficiaries
3,610
19,092 claims
Per beneficiary
$14,050
$62.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $19,460,895 |
| 2021 | $37,530,854 |
| 2022 | $45,127,244 |
| 2023 | $49,718,992 |
| 2024 | $50,721,486 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Safety of Istradefylline Among Parkinson Disease Adjunctive Therapies: A Systematic Review and Meta-analysis of Randomized Controlled Studies.
Torres-Yaghi Y, Qian J, Cummings H, et al. · Clin Neuropharmacol 2025 · Systematic Review, Meta-Analysis
- Efficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis.
Wang XL, Feng ST, Chen B, et al. · Neurosci Lett 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- The effect of istradefylline for Parkinson's disease: A meta-analysis.
Sako W, Murakami N, Motohama K, et al. · Sci Rep 2017 · Meta-Analysis
- Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
Mizuno Y, Kondo T · Mov Disord 2013 · Multicenter Study, Randomized Controlled Trial
- Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Hauser RA, Shulman LM, Trugman JM, et al. · Mov Disord 2008 · Clinical Trial, Phase III, Multicenter Study
- Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson's disease: A single-arm, open-label, prospective, multicenter study.
Iijima M, Orimo S, Terashi H, et al. · Expert Opin Pharmacother 2019 · Clinical Trial, Phase I, Multicenter Study
Sponsor: Kyowa Kirin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.